Copertina

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Julia Karady, Thomas Mayrhofer, Borek Foldyna, Michael T. Lu, Nandini Meyersohn, Udo Hoffmann, Oluwafemi Balogon, Neha Pagidipati, Svati Shah, Pamela S. Douglas, Maros Ferencik, Kathleen Corey
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
di: Changhu Sun, et al.
Pubblicazione: (2025)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
di: Na Tian, et al.
Pubblicazione: (2025)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
di: Takao Miwa, et al.
Pubblicazione: (2026)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
di: C. C. Mark Cheah, et al.
Pubblicazione: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
di: Xiao‐Dong Zhou, et al.
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
di: Shun‐Ichi Wakabayashi, et al.
Pubblicazione: (2026)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2026)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
di: Catherine Z. Tang, et al.
Pubblicazione: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
di: Cong Dai, et al.
Pubblicazione: (2024)

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure
di: Charlotte Mouliade, et al.
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
di: Isabel Carbery, et al.
Pubblicazione: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
di: Abdulrahman Ismaiel
Pubblicazione: (2026)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
di: Paul Y. Kwo, et al.
Pubblicazione: (2026)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
di: Yash Hegde, et al.
Pubblicazione: (2026)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
di: Luis Calzadilla Bertot, et al.
Pubblicazione: (2025)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
di: Anupam Kumar Singh, et al.
Pubblicazione: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
di: Anupam Kumar Singh, et al.
Pubblicazione: (2026)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Shinya Yokoyama, et al.
Pubblicazione: (2025)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
di: Ze‐Hua Zhao, et al.
Pubblicazione: (2025)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
di: Mohamad Jamalinia, et al.
Pubblicazione: (2024)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
di: Kaleb Tesfai, et al.
Pubblicazione: (2025)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
di: Lynna Chen, et al.
Pubblicazione: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
di: Joyce Wing Yan Mak
Pubblicazione: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
di: Aurelien Amiot, et al.
Pubblicazione: (2025)

Editorial: Upadacitinib in Perianal Crohn's Disease
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
di: Benedikt Silvester Hofer, et al.
Pubblicazione: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease
di: Jeli Mendoza, et al.
Pubblicazione: (2024)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
di: Matthew D. Coates, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
di: Marco Vincenzo Lenti, et al.
Pubblicazione: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
di: Karen Cheuk‐Ying Ho, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
di: Agnes Hiu Yan Ho, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Editorial: Distinct Challenges of Paediatric From Adult‐Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children
di: Alessandro Molinaro, et al.
Pubblicazione: (2024)